Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemic, should be screened periodically, at least by Otoacoustic Emissions (OAEs) in order to detect early manifestations of possible cochlear ototoxic damages.
Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency
Andrea Ciorba
Primo
;Stefano PelucchiPenultimo
;Stavros HatzopoulosUltimo
2020
Abstract
Aim of this paper is to remind the risk of ototoxicity when using chloroquine and hydroxychloroquine, in particular as prophylactic agents against SARS-CoV-2, during the pandemic. Healthy subjects taking chloroquine and hydroxychloroquine as prophylactic agents against SARS-CoV-2, during the pandemic, should be screened periodically, at least by Otoacoustic Emissions (OAEs) in order to detect early manifestations of possible cochlear ototoxic damages.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ototox prevention.pdf
accesso aperto
Descrizione: versione editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
Creative commons
Dimensione
268.57 kB
Formato
Adobe PDF
|
268.57 kB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
